Skip to main content

Advertisement

Table 2 Risk of modeled health events according to treatment

From: Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

  ARISTOTLE Rate per 100 patient years1 Second line treatment Rate per 100 patient years
Apixaban Warfarin ASAc No antithrombotic treatment
Ischemic stroke by CHADS2-score
 0–1 (34 % of patients) 0.521 0.458   
 2 (35.8 % of patients) 0.950 0.934   
 3–6 (30.2 % of patients) 1.534 1.944   
 Weighted average/average 0.981 1.021 2.280 2.812
Hemorrhagic stroke 0.254 0.512 0.388
Other intracranial bleed 0.076 0.288 1.455
Other major bleed: gastrointestinal 0.680 0.795 1.455
Other major bleed: not gastrointestinal 1.110 1.476 1.455
Clinically relevant non-major bleed 2.083 2.995 1.811
Myocardial infarction 0.530 0.610 0.616 0.8563
Systemic embolism 0.090 0.100 0.600 0.4864
Mortality for the trial durationa 3.0825 3.3404   
Other cardiovascular hospitalizations   
Treatment discontinuationb 13.177 14.405   
  1. aOther cause mortality after the trial period was estimated by fitting a Gompertz survival function to the Finnish life tables
  2. bFor reasons other than modeled events
  3. cThe relative risk estimates from the AVERROES trial (Connolly et al. 2011) were applied to the apixaban event rates in the ARISTOTLE trial (Granger et al. 2011)
  4. 1Dorian et al. (2014)
  5. 2The ASA event rates were transformed using a relative risk (RR) reduction of 0.19 (Lip and Lim 2007) for ASA versus placebo
  6. 3The ASA event rates were transformed using RR = 0.72 (Yerman et al. 2007) for ASA versus placebo
  7. 4An RR of 0.19 for stroke was assumed to apply for SE as well